Aspire Biopharma to Present at Sidoti Virtual Investor Conference

Aspire Biopharma Holdings will present at the Sidoti Virtual Investor Conference on August 20. Kraig Higginson, Interim CEO, will present at 1:45 PM Eastern. Virtual one-on-one meetings will be available on August 20 and 21. A replay of the presentation will be available on Aspire's website. Aspire has developed a patent-pending drug and supplement delivery technology that aims to deliver substances rapidly and precisely to the bloodstream, bypassing the gastrointestinal tract.

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) will present at the Sidoti Virtual Investor Conference on August 20, 2025. The company's interim CEO, Kraig Higginson, will deliver a presentation at 1:45 PM Eastern. Investors are invited to attend the virtual event and participate in one-on-one meetings with the company's leadership on August 20 and 21. A replay of the presentation will be available on Aspire's investor relations website [1].

Aspire Biopharma has developed a patent-pending drug and supplement delivery technology that aims to deliver substances rapidly and precisely to the bloodstream, bypassing the gastrointestinal tract. This innovative technology is designed to minimize negative side effects associated with traditional oral administration methods [2].

The company's recent Form 10-Q report highlights significant financial developments. Total operating expenses for the second quarter of 2025 were $799,890, a substantial increase from the same period in 2024, driven by higher general and administrative expenses and research and development costs. The net loss for the same period was $1,981,293, compared to $96,923 in 2024. These increases are largely attributed to higher operating and interest expenses [2].

Aspire is focused on developing and marketing novel sublingual delivery mechanisms for known drugs and supplements. The company's high-dose sublingual aspirin product, 'Instaprin', is currently in clinical trials, with results expected in mid-August 2025. Aspire has partnered with Glatt, a contract manufacturer, to produce its products for clinical trials and potential commercial use [2].

The company plans to submit a section 505(b)(2) New Drug Application (NDA) for its high-dose aspirin product following the analysis of clinical trial results. Additionally, Aspire is exploring the potential for an OTC FDA Monograph permit to expedite market entry. The company is also developing a sublingual melatonin sleep-aid product in various doses [2].

Investors can register for the Sidoti Virtual Investor Conference and one-on-one meetings through Sidoti's registration platform. A replay of the presentation will be available on Aspire's investor relations website [1].

References:
[1] https://www.stocktitan.net/news/ASBP/aspire-biopharma-holdings-inc-to-present-at-sidoti-virtual-investor-8aqu3j93kfcr.html
[2] https://www.tradingview.com/news/tradingview:b03a5d4f96b7e:0-aspire-biopharma-holdings-inc-sec-10-q-report/